Bookmarks
ID-474: Cost-modelling the introduction of pharmacotherapy in adult weight-management service pathways in Northwest London
Safe People
Organisation name
ICHNT
Applicant name(s)
Funders/ Sponsors
Safe Projects
Project ID
ID-474
Lay summary
This project will support the work led by the Health Equity Healthy Weight Reference Group & NWL ICB Medicine Management to assess the costs and benefits of the implementation of pharmacotherapy for weight management in NWL weight management pathway.
Public benefit statement
Obesity is a complex condition where genetics, mental health, cultural and lifestyle factors are intertwined. Its management requires a structural approach including diet, exercise, mental health support and pharmacotherapy. Recently NICE approved the phased introduction ofGLP-1 agonists drugs, such as tirzepatide, for weight reduction in NHS pathways. It is estimated that 3.4 million people in England are eligible for the drug, therefore, the roll out must be carefully planned to ensure proper distribution of resources to meet the variety of health needs across the population. Results of the study will inform the implementation of pharmacotherapy for weight reduction in NWL services to ensure those that are at higher risk of obesity related complications in NWL can access the therapy. This is expected to have an impact in NWL population health.
Other approval committees
Latest approval date
17/07/2025
Safe Data
Dataset(s) name
Safe Setting
Access type
TRE